Evidence map›Paper›PMID 28631186›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2017

Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.

Concha López-Ginés, Lara Navarro, Lisandra Muñoz-Hidalgo, Enrique Buso, José Manuel Morales, Rosario Gil-Benso, Mariela Gregori-Romero, Javier Megías, Pedro Roldán, Remedios Segura-Sabater and 3 more

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Macropinocytosis: mechanism and targeted therapy in cancers.American journal of cancer research · 2021
    Review
  3. Whole-exome sequencing,American journal of cancer research · 2021
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Concha López-GinésDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain. concha.lopez@uv.es.
Lara NavarroFundación de Investigación del Hospital Clínico Universitario de Valencia / INCLIVA, Valencia, Spain.
Lisandra Muñoz-HidalgoFundación de Investigación del Hospital Clínico Universitario de Valencia / INCLIVA, Valencia, Spain.
Enrique BusoUnidad Central de Investigación en Medicina, Universitat de València, València, Spain.
José Manuel MoralesUnidad Central de Investigación en Medicina, Universitat de València, València, Spain.
Rosario Gil-BensoDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain.
Mariela Gregori-RomeroDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain.
Javier MegíasDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain.
Pedro RoldánServicio de Neurocirugía, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Remedios Segura-SabaterFundación de Investigación del Hospital Clínico Universitario de Valencia / INCLIVA, Valencia, Spain.
José Manuel Almerich-SillaDepartamento de Estomatología, Universitat de València, Valencia, Spain.
Daniel MonleónDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain.
Miguel Cerdá-NicolásDepartamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain. jose.m.cerda@uv.es.
Universitat de València · ESHospital Clínico Universitario de Valencia · ESINCLIVA Health Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlioblastoma (GB) is the most frequent and most malignant primary brain tumor in adults. Previously, it has been found that both genetic and epigenetic factors may play critical roles in its etiology and prognosis. In addition, it has been found that the epidermal growth factor receptor gene (EGFR) is frequently over-expressed and amplified in primary GBs. Here, we assessed the promoter methylation status of 10 genes relevant to GB and explored associations between these findings and the EGFR gene amplification status.

methodsTumor samples were obtained from 36 patients with primary GBs. In addition, 6 control specimens were included from patients who were operated for diseases other than brain tumors. The amplification status of the EGFR gene, and its deletion mutant EGFRvIII, were evaluated using FISH and MLPA, respectively. The IDH1/2 gene mutation status was verified using Sanger sequencing. A commercial DNA methylation kit was used to assess the promoter methylation status of 10 pre-selected genes. Metabolic profiles were measured using HR-MAS NMR spectroscopy. The EGFR and ARF1 mRNA expression levels were quantified using qRT-PCR.

resultsOf the 10 genes analyzed, we found that only ARF1 promoter hypermethylation was significantly associated with EGFR gene amplification. ARF1 is a GTPase that is involved in vesicle trafficking and the Golgi apparatus. Subsequent tumor metabolism measurements revealed a positive association between EGFR amplification and different membrane precursors and methyl-donor metabolites. Finally, we found that EGFR gene amplifications were associated with distinct tumor infiltration patterns, thus representing a putative novel functional association between EGFR gene amplification and ARF1 gene promoter methylation in GB.

conclusionsThe results reported here provide a basis for a new hypotheses connecting EGFR gene amplification in GB cells with ARF1 gene promoter methylation, vesicle trafficking, membrane turnover and tumor metabolism. The mechanism(s) underlying these connections and their functional consequences remain to be established.

Indexed as

DNA MethylationGene AmplificationADP-Ribosylation Factor 1AdultAgedBrain NeoplasmsErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGlioblastomaHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedMutationPrognosisADP-Ribosylation Factor 1EGFR protein, humanErbB ReceptorsARF1DNA methylationEGFR amplificationGlioblastomaMetabolomics

Identifiers

PMID28631186
PMCPMC13001540
OpenAlexW2702685723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.